Several activist hedge funds have narrowly avoided steep losses after Kimberly-Clark’s $40bn acquisition of Kenvue, the Johnson & Johnson consumer health spin-off, reversed a brutal selloff in the stock, according to a report by the Wall Street Journal.
DE Shaw, one of Kenvue’s largest shareholders with a roughly 3% stake, had been staring at paper losses exceeding $200m following a 22% slide in Kenvue’s shares. The drop came after the Trump administration controversially linked acetaminophen, Tylenol’s active ingredient, to autism – claims widely dismissed by scientists and medical experts.
The reports cites unnamed people familiar with the matter as highlighting that Kimberly-Clark’s all-cash bid at $21.01 per share now leaves DE Shaw roughly breaking even on its investment.
Other hedge fund investors – including Toms Capital, Starboard Value, and Third Point – were also exposed to Kenvue’s downturn. Toms Capital, which built a 3% position earlier this year, argued as recently as October that litigation fears had obscured Kenvue’s underlying brand value, citing assets such as Aveeno, Band-Aid, Listerine, and Neutrogena.
Starboard Value had launched a proxy campaign earlier in the year that placed CEO Jeff Smith on Kenvue’s board, betting on operational reforms and potential strategic alternatives. Despite the bid falling below Starboard’s initial entry price near $23, the deal offers activists a partial exit and valuation floor in an otherwise challenged consumer health sector.
The transaction delivers a lifeline to both Kenvue’s investors and its activist backers, who had pushed for structural change but were blindsided by political and legal headwinds. Kimberly-Clark and Kenvue project roughly $2bn in cost synergies within three years of closing.
